米国の局所皮膚薬市場 – 業界動向と2030年までの予測

米国の局所皮膚薬市場の分析と規模

近年の研究開発投資の急増により、潜在的な医薬品候補が徐々に増加しており、2023～2030年の予測期間に外用皮膚薬市場を牽引すると予想されています。米国ではジェネリック医薬品の処方が増加しているため、ジェネリック医薬品のマーケティングに重点を置く新しい市場プレーヤーが増え、市場の成長の大きな原動力となっています。政府や民間組織による製薬業界の発展に向けた取り組みが増えていることも、市場の成長を後押ししています。

データブリッジ市場調査は、2023年から2030年の予測期間における外用皮膚薬市場の成長率を分析しています。外用皮膚薬市場の予想CAGRは、上記の予測期間において約9％になる傾向があります。市場価値は2022年に47億米ドルで、2030年までに93億7000万米ドルまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

米国の局所皮膚薬市場の範囲とセグメンテーション

市場の定義

外用皮膚薬は、皮膚に局所的に塗布するタイプの製品です。このような薬は主に皮膚疾患の回復に使用され、一部の皮膚障害の予防に頻繁に使用されます。一方、皮膚科用薬は、通常のスキンケアで皮膚を保護するために広く使用されています。外用薬は、抗真菌薬、コルチコステロイド、局所麻酔薬、抗ウイルス薬、抗生物質、抗ニキビ薬、かゆみ止め薬、その他の外用薬に分類されます。

米国の局所皮膚薬市場の動向

ドライバー

• 高齢者人口の増加

高齢者は加齢とともに正常に機能する能力を失い、多くの皮膚疾患を引き起こします。さらに、加齢とともに、紫外線（UV）に対する感受性が高まり、感染症にかかりやすくなり、傷の治りが遅くなり、皮下脂肪が減少するなど、身体は多くの問題に悩まされるようになります。多くの皮膚疾患の可能性が高まるため、皮膚科用医薬品の需要が高まっています。

• 政府の取り組みの強化

The initiatives by governments and private organizations to develop many topical drugs are driving the growth of the market. Additionally, the growing number of approvals for dermatology products is boosting the growth of the market. For instance, pharmaceutical company AbbVie Inc. announced that the U.S. Food and Drug Administration approved Rinvoq (upadacitinib) for the treatment of patients with active psoriatic arthritis in December 2021. Though, the increasing presence of acne treatment alternatives such as light or laser therapy, micro-needling, chemical peels, microdermabrasion, and lesion removal is anticipated to restrain the growth of the dermatology market during the forecast period 2023-2030.

Opportunities

• Increasing Cases of Skin Disorders

The increasing frequency of skin cancer and other associated skin disorders or other skin issues such as vitiligo, acne, and dermatosis combined with the growing demand of effective drugs are the most major factors increasing the growth for this market. Furthermore, fungal infection and acne were more incident in the adolescent age group, accounting for around 17.4% and 30.4%, respectively. Around 84.5 million Americans, one in four, were largely impacted by skin disease. It has been seen that acne is the most common skin condition in the U.S., affecting more than 50 million Americans each year. Acne typically begins in puberty and affects various adolescents and young adults. As per the records of the World Psoriasis Day consortium, around 125 million people globally which means that 2 to 3% of the total population suffer from psoriasis. Therefore, this boosts the market growth. 

Restraints/Challenges

• High Cost of Drugs

There are numerous drugs that are related with the disease such as targeted therapy and chemotherapy. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone, and thalidomide. These drugs process causes the increased rate of cost. Thus, these factors restrict the market growth.

This topical derma drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the topical derma drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

U.S. Topical Derma Drugs Market Scope

The topical derma drugs market is segmented on the basis of severity, drug class, formulation, site, application, population type, mode of purchase, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Severity

• Mild to Moderate
• Moderate to Severe

Drug Class

• Anti-Fungal
• Corticosteroids
• Local Anaesthetics
• Anti-Virals
• Antibiotics
• Anti-Acne Agents
• Anti-Itch Agents
• Miscellaneous Topical Agents
• Others

Formulation

• Patches
• Gel
• Ointment
• Cream
• Foams
• Others

Site

• Surface of the Skin
• Epidermis and Dermis

Application

• Acne
• Cold Sores
• Hives
• Actinic Keratosis
• Carbuncle
• Rosacea
• Eczema
• Psoriasis
• Lupus
• Contact Dermatitis
• Vitiligo
• Warts
• Ringworm
• Impetigo
• Others

Population Type

• Children
• Adults

Mode of Purchase

• Prescription
• Over the Counter (OTC)

End User

• Hospitals
• Specialty Clinics
• Academic & Research Institutes
• Others

Competitive Landscape and U.S. Topical Derma Drugs Market Share Analysis

The topical derma drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, U.S. presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to topical derma drugs market.

Key players operating in the topical derma drugs market include:

• Sanofi (France)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc. (U.S.)
• Sanofi (France)
• Amgen inc. (U.S.)
• Lilly (U.S.)
• AstraZeneca (U.K.)
• AbbVie Inc (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• LEO Pharma A/S (Denmark)
• Merck & Co., Inc (U.S.)
• Bausch Health Companies Inc (Canada)
• Bristol-Myers Squibb Company (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)

SKU-62823